Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
May guide superantigen-targeted therapies in toxic shock; leaves open clinical validation in autoimmune diseases.
Malak Kotb (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: